GH Research GHRS 深 沪
等待开盘 09-30 09:30:00 美东时间
24.645
+1.225
+5.23%
华盛通- 最 高24.99
- 今 开23.39
- 成交量 95.60万股
- 最 低 23.12
- 昨 收 23.42
- 总市值 16.92亿
- 52周最高 31.439
- 市盈率 静 --
- 换手率 1.39%
- 52周最低 12.04
- 委 比 2.44%
- 总股本 6864.23万
- 历史最高 31.439
- 量 比 3.32
- 振 幅 7.98%
- 历史最低 5.05
- 每 手 1
- 风险率 5.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.
08-07 02:19
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the same period last year.
08-06 19:19
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GH Research PLC reported financial results for Q2 2026, with cash, cash equivalents, and marketable securities totaling $362.7 million. The company achieved alignment with the FDA on CMC and device plans for Phase 3, successfully completed Phase 1 trials GH001-HV-106 and GH001-HV-109, and strengthened its US and EU mebufotenin patents. Phase 2a results for postpartum depression were published in The Journal of Clinical Psychiatry. R&D expenses ro...
08-06 11:00
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44
Wells Fargo analyst Benjamin Burnett initiates coverage on GH Research (NASDAQ:GHRS) with a Overweight rating and announces Price Target of $44.
07-27 20:49
巨头并购、政策开闸、数据井喷……迷幻药变天前夜，市场收到一记38亿美元的多头信号
上周四，礼来公司(LLY.US)宣布将以高达38亿美元的价格收购临床阶段迷幻药物制造商AtaiBeckley(ATAI.US)。这一动作标志着，大型制药企业正日...
07-20 08:48
Why Is GH Research Stock Trading Higher on Thursday?
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion. Bloomberg was the first to report the deal. AtaiBeckley is one ...
07-17 00:36
